MitoImmune Therapeutics
PrivateLast Round
Series B
Extension
Sep 25, 2023
Total Funding Raised
$38.81M
Company Overview
MitoImmune Therapeutics operates in Healthcare & Life Sciences and is based in Seoul. Its latest recorded funding round was a Series B Extension round in September 2023.
MitoImmune Therapeutics is a biotechnology company that develops innovative drugs targeting mitochondrial dysfunction and regulated necrotic cell death.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
MitoImmune Therapeutics Comparables
Compare MitoImmune Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Morningside | 78% | |
| SeaBeLife | 77% | |
| Pretzel Therapeutics | 77% |
For institutional investors. Book with your work email.
MitoImmune Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B Extension | Sep 25, 2023 | ||||
| Series B | Feb 26, 2021 | ||||
| Series A | Apr 1, 2019 |
For institutional investors. Book with your work email.
MitoImmune Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| BNH INVESTMENT | Series A, Series B |
| SL Investment | Series A, Series B |
| KB Investment | Series A, Series B |
| Orion Capital Management | Series B |
| K-Ground Ventures | Series B Extension |
| GTO Investment | Series B |
| CJ Investment | Series B |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Mar 4, 2026
Monthly visitors increased 56% MoM.
- Jan 7, 2026
Monthly visitors grew 347% MoM, reaching 1.9K.
For institutional investors. Book with your work email.
MitoImmune Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about MitoImmune Therapeutics's valuation, stock price, and market status.
Is MitoImmune Therapeutics a public or private company?
MitoImmune Therapeutics is a private company.
What is the current stock price of MitoImmune Therapeutics?
MitoImmune Therapeutics is a private company, so its shares have no public market price. Caplight tracks MitoImmune Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is MitoImmune Therapeutics worth (valuation)?
Valuation information for MitoImmune Therapeutics is not publicly available.
Can I buy MitoImmune Therapeutics stock?
MitoImmune Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was MitoImmune Therapeutics's last funding round?
MitoImmune Therapeutics's most recent funding round was Series B Extension on September 25, 2023.
Who are the main investors in MitoImmune Therapeutics?
Key investors in MitoImmune Therapeutics include Korea Development Bank.
Will MitoImmune Therapeutics IPO soon?
No public IPO plans have been announced for MitoImmune Therapeutics.
How can I track MitoImmune Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in MitoImmune Therapeutics's shares on secondary markets.